Publications by authors named "Manu Mehta"

Claim this Profile
C
Correction to: Diurnal variability and trends of air pollution in association with heat stress over five Indian megacities.
Manu Mehta, Shivani, Khushbu Dahiya, Somya Garg, Ranu Gadi

Environ Monit Assess· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diurnal variability and trends of air pollution in association with heat stress over five indian megacities.
Manu Mehta, Shivani, Khushbu Dahiya, Somya Garg, Ranu Gadi

Environ Monit Assess· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A review of urban heat island mapping approaches with a special emphasis on the Indian region.
Renugadevi N, Manu Mehta, Gideon Daniel Giftson T

Environ Monit Assess· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Substantial overlap between NAFLD and MASLD with comparable disease severity and non-invasive test performance: An analysis of the Indian Consortium on MASLD (ICOM-D) cohort.
Arka De, Manu Mehta, Ajay Duseja,

J Hepatol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Central Obesity is an Independent Determinant of Advanced Fibrosis in Lean Patients With Nonalcoholic Fatty Liver Disease.
Arka De, Naveen Bhagat, Manu Mehta, Priya Singh, Sahaj Rathi

J Clin Exp Hepatol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Machine learning improves the prediction of significant fibrosis in Asian patients with metabolic dysfunction-associated steatotic liver disease - The Gut and Obesity in Asia (GO-ASIA) Study.
Nipun Verma, Ajay Duseja, Manu Mehta, Arka De, Huapeng Lin

Aliment Pharmacol Ther· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with NAFLD.
Arka De, Naveen Bhagat, Manu Mehta, Sunil Taneja, Ajay Duseja

J Hepatol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lean Indian patients with non-alcoholic fatty liver disease (NAFLD) have less metabolic risk factors but similar liver disease severity as non-lean patients with NAFLD.
Arka De, Manu Mehta, Priya Singh, Naveen Bhagat, Suvradeep Mitra

Int J Obes (Lond)· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infrared spectroscopic laser scanning confocal microscopy for whole-slide chemical imaging.
Kevin Yeh, Ishaan Sharma, Kianoush Falahkheirkhah, Matthew P Confer, Andres C Orr, Manu Mehta

Nat Commun· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-alcoholic fatty liver disease development: A multifactorial pathogenic phenomena.
Aamir Bashir, Ajay Duseja, Arka De, Manu Mehta, Pramil Tiwari

Liver Res· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinicopathological Profile and Outcome of a Large Cohort of Patients with Nonalcoholic Fatty Liver Disease from South Asia: Interim Results of the Indian Consortium on Nonalcoholic Fatty Liver Disease.
Ajay Duseja, Shivaram P Singh, Manu Mehta, Shalimar, Jayanthi Venkataraman, Varun Mehta, Rajiv Mehta

Metab Syndr Relat Disord· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NAFLD vs. MAFLD - It is not the name but the disease that decides the outcome in fatty liver.
Arka De, Nishat Ahmad, Manu Mehta, Priya Singh, Ajay Duseja

J Hepatol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FibroScan-AST (FAST) Score for Nonalcoholic Steatohepatitis - Validation in an Indian Cohort.
Arka De, Amarjit Keisham, Saurabh Mishra, Manu Mehta, Nipun Verma

J Clin Exp Hepatol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sofosbuvir and Velpatasvir combination is safe and effective in treating chronic hepatitis C in end-stage renal disease on maintenance haemodialysis.
Sunil Taneja, Ajay Duseja, Manu Mehta, Arka De, Nipun Verma

Liver Int· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association between nonalcoholic fatty liver disease and inflammatory periodontal disease: A case‑control study.
Ajay Duseja, Gurparkash Singh Chahal, Ashish Jain, Manu Mehta, Aditya Ranjan

J Indian Soc Periodontol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease (NAFLD): a randomised, double-blind, proof of concept study.
Ajay Duseja, Subrat K Acharya, Manu Mehta, Shruti Chhabra,

BMJ Open Gastroenterol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-Dose Sofosbuvir Is Safe and Effective in Treating Chronic Hepatitis C in Patients with Severe Renal Impairment or End-Stage Renal Disease.
Sunil Taneja, Ajay Duseja, Arka De, Manu Mehta, Raja Ramachandran

Dig Dis Sci· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Renal Dysfunction in Patients With Nonalcoholic Fatty Liver Disease is Related to the Presence of Diabetes Mellitus and Severity of Liver Disease.
Ram V Nampoothiri, Ajay Duseja, Manish Rathi, Swastik Agrawal, Naresh Sachdeva, Manu Mehta

J Clin Exp Hepatol· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vitamin D supplementation in patients with nonalcoholic fatty liver disease: A randomized controlled trial.
Mallikarjun Sakpal, Sandeep Satsangi, Manu Mehta, Ajay Duseja, Sanjay Bhadada

JGH Open· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Can Alcoholic Liver Disease and Nonalcoholic Fatty Liver Disease Co-Exist?
Manu Mehta, Sandeep Satsangi, Ajay Duseja, Sunil Taneja, Radha K Dhiman

J Clin Exp Hepatol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual treatment with sofosbuvir plus ribavirin is as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis C.
Sandeep Satsangi, Manu Mehta, Ajay Duseja, Sunil Taneja, Radha K Dhiman

J Gastroenterol Hepatol· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Obstructive sleep apnea is an important predictor of hepatic fibrosis in patients with nonalcoholic fatty liver disease in a tertiary care center.
Swastik Agrawal, Ajay Duseja, Ashutosh Aggarwal, Ashim Das, Manu Mehta

Hepatol Int· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis